Stocks · News reference
BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M Est
BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $666.201 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioCryst Pharma shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform rating and lowered its price target from $13 to $11.
RBC Capital Downgrades BioCryst Pharma to Sector Perform, Lowers Price Target to $11
RBC Capital analyst Brian Abrahams downgrades BioCryst Pharma (NASDAQ:BCRX) from Outperform to Sector Perform and lowers the price target from $13 to $11.
Needham Reiterates Buy on BioCryst Pharma, Maintains $16 Price Target